To report a case of hypophosphatemic osteomalacia induced by adefovir dipivoxil and review existing literature on the condition, highlighting its clinical significance.
Key Findings:
Adefovir dipivoxil can induce hypophosphatemic osteomalacia and Fanconi syndrome, a condition characterized by renal tubular dysfunction.
Discontinuation of adefovir and correction of metabolic abnormalities can significantly improve bone mineral density.
Persistent low bone mineral density may indicate underlying osteoporosis despite resolution of osteomalacia, highlighting the need for ongoing assessment.
Interpretation:
In postmenopausal women on long-term adefovir therapy, it is crucial to identify and manage osteomalacia first, followed by evaluation for osteoporosis to avoid misdiagnosis, which can impact treatment decisions.
Limitations:
Single case study limits generalizability and may not represent broader patient populations.
Long-term outcomes and effects of treatment on bone density require further investigation to establish comprehensive management guidelines.
Conclusion:
This case underscores the importance of monitoring bone health in patients receiving adefovir dipivoxil and highlights the need for comprehensive evaluation of bone density post-treatment to ensure timely intervention.
